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Abstract: Ulcerative colitis is a chronic inflammatory bowel disease that can lead to 
derangements in the growth, nutritional status, and psychosocial development of affected 
children. There are several medical options for the induction and maintenance of disease 
remission, but the benefits of these medications need to be carefully weighed against the risks, 
especially in the pediatric population. As the etiology of the disease has become increasingly 
understood, newer therapeutic alternatives have arisen in the form of biologic therapies, which 
are monoclonal antibodies targeted to a specific protein or receptor. This review will discuss 
the classical treatments for children with ulcerative colitis, including 5-aminosalicylates, 
corticosteroids, thiopurine immunomodulators, and calcineurin inhibitors, with a particular 
focus on the newer class of anti-tumor necrosis factor-α agents.
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Introduction
Inflammatory bowel disease (IBD) is the term used to describe idiopathic disorders 
associated with chronic inflammation of the gastrointestinal tract and includes Crohn’s 
disease (CD) and ulcerative colitis (UC).1 It has recently been estimated that over 
1 million people in the United States are affected by IBD, with up to 25% of these 
individuals being diagnosed before 20 years of age.2 This review focuses on UC, which 
is a disease marked by mucosal inflammation that generally begins in the rectum and 
involves a variable extent of proximal colon.1 A proper diagnosis of UC requires 
the combination of a detailed clinical history, physical examination, radiographic 
features, endoscopic evaluation, and tissue histology. While the pathogenesis of UC 
is not fully understood, genetic, immunologic, and environmental factors are thought 
to play a role.
UC in children has several distinct features from the disease seen in adults. Common 
presenting symptoms of pediatric UC include diarrhea, hematochezia, abdominal pain, 
and weight loss; however, interestingly, constipation can also be an early symptom.3,4 
Adults often have disease that is limited to the rectosigmoid area of the colon, but 
more than 80% of children have pancolitis.3 Additionally, UC appears to manifest 
more aggressively in children with moderate-to-severe symptoms that require escala-
tion of medical and surgical therapies. A retrospective review of children and adults 
with UC who underwent total proctocolectomy found that the duration of symptoms 
before surgery was significantly shorter and the disease distribution significantly more 
extensive in the pediatric patients.5
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Goals of therapy for pediatric UC include induction and 
maintenance of disease remission, prevention of cancer 
of the affected bowel, improvement in quality of life, and 
facilitation of normal growth and development.6 Surgery, 
including proctocolectomy with ileal pouch-anal anasto-
mosis, can be curative. However, surgery is not without 
its complications, including chronic pouchitis and fecal 
incontinence, so medical therapies are used to acutely 
induce remission of symptoms and then maintain long-term 
remission.7 As shown in Table 1, pharmacologic therapy 
for UC includes the following categories of medications: 
5-aminosalicylates (5-ASAs), corticosteroids, thiopurine 
immunomodulators, calcineurin inhibitors, antibiotics, 
probiotics, and anti-tumor necrosis factor (TNF)-α agents. 
Biologic therapies, including anti-TNF-α agents, are an 
expanding class of medications that offer exciting new treat-
ment options for UC since they target unique pathways within 
the pathogenesis of the disease. There is little rationale in UC 
for a top-down approach to treatment, where immunomodu-
lators and anti-TNF-α agents are instituted much earlier in 
the disease course; instead, most patients are treated with 
an accelerated step-up approach, where medications are 
prescribed in sequential order with regular assessment of the 
disease and adjustment of the treatment as needed to achieve 
remission.8 Therefore, this review will focus on the use of 
each of the aforementioned medication classes for pediatric 
UC of escalating severity.
5-aminosalicylates
5-ASAs are the first-line treatment for the induction 
and maintenance of remission of mild-to-moderate 
UC.9 They have a wide range of anti-inflammatory and 
immunomodulatory properties, including inhibition of 
5-lipoxygenase, scavenging of reactive oxygen metabolites, 
and inhibition of interleukin-1 synthesis.7 Free 5-ASA is 
almost completely absorbed from the stomach and proximal 
small intestine, so sustained-release preparations have been 
developed to deliver the medication to more distal sites of 
inflammation. Sulfasalazine has traditionally been used in 
UC and is composed of 5-ASA linked to sulfapyridine via 
a diazo bond that is cleaved by colonic bacteria. However, 
the sulfapyridine moiety has several dose-limiting side 
effects, including headaches, nausea, anorexia, and reversible 
oligospermia, that can be seen in approximately one-third 
of patients.10 Newer formulations, including mesalamine, 
olsalazine, and balsalazide, utilize pH- or time-dependent 
delivery systems to release higher concentrations of 5-ASA 
at various sites of the small intestine and colon with fewer 
side effects, thus allowing treatment to be tailored to the 
extent of the disease and the preferred method of medication 
administration.
In children, pharmacokinetic data are limited, so dosage 
recommendations are largely extrapolated from adult 
studies. A retrospective review of all children with IBD 
treated at Sainte-Justine Hospital in Montreal, Canada 
between 1984 and 1994 investigated the modalities of use, 
dosage, and safety of a particular mesalamine preparation, 
Asacol (Medeva Pharma Suisse, Geneva, Switzerland).11 
A total of 153 children (120 CD, 33 UC) had been treated 
with this 5-ASA preparation alone or in combination 
with other medications. The children with UC received 
an average daily dose of 36–40.5 mg/kg with a significant 
improvement in hematocrit and decrease in sedimentation 
rate while on therapy. Overall, only eight of the 153 children 
(5.2%) experienced side effects, with over half reporting 
an exacerbation of vomiting, abdominal pain, or diarrhea.
5-ASA can also be administered in the form of an 
enema or a suppository for management of distal colonic 
inflammation. A multicenter, open-label, nonrandomized 
study enrolled 49 children with ulcerative proctitis and treated 
Table  1  Classes  of  medications  used  in  the  management  of 
pediatric ulcerative colitis
Medication class Clinical indications Common side effects
5-aminosalicylates Mild-to-moderate  
disease
Headaches, 
nausea, diarrhea, 
photosensitivity
Corticosteroids Acute  
moderate-to-severe  
disease
Hyperglycemia, 
hypertension, growth 
failure, weight gain, 
osteopenia, mood 
disturbances
Thiopurine 
immunomodulators
Maintenance of  
remission of  
moderate-to-severe  
disease
Bone marrow 
suppression, hepatitis, 
pancreatitis, infections, 
malaise, rashes
Calcineurin  
inhibitors
Acute severe  
or fulminant disease
Nephrotoxicity, 
infections, seizures, 
hirsutism, hypertension, 
headaches
Antibiotics Adjunctive therapy  
for active disease; 
pouchitis
Specific to individual 
antibiotics
Probiotics Adjunctive therapy  
for active disease; 
recurrent pouchitis
Limited data
Anti-TNF-α agents induction and  
maintenance of  
remission of moderate- 
to-severe disease
Hypersensitivity 
reactions, headaches, 
nausea, abdominal pain, 
infections
Abbreviation: TNF-α, tumor necrosis factor-α.
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them with a 5-ASA 500-mg suppository daily for 6 weeks.12 
The main outcome measure was reduction in the disease 
activity index score, which considered stool frequency, 
urgency, blood in the stools, extracolonic features, and 
overall well-being of the patient. The study found significant 
reductions from baseline in the disease activity index score 
at weeks 3 and 6. Only four patients required dose escalation 
after 3 weeks due to worsening of or no change in clinical 
condition. Forty-one children (83.7%) reported at least one 
adverse event, with 61.2% experiencing gastrointestinal 
symptoms such as abdominal pain, vomiting, or diarrhea; 
however, the majority of these side effects were mild and 
considered unrelated to study therapy.
Corticosteroids
Corticosteroids, such as prednisone and methylprednisolone, 
have been widely used in the acute treatment of moderate-
to-severe UC because of their powerful anti-inflammatory 
properties and rapidity of action. A recent multicenter, 
prospective, observational registry study found that 79% of 
children newly diagnosed with UC received corticosteroids 
in the first year of diagnosis, with the majority initiating 
corticosteroids within 30 days.13 These children were noted 
to have more severe disease activity and lower hemoglobin 
and serum albumin levels than children who did not receive 
corticosteroids.
Corticosteroids are effective in inducing disease remis-
sion, but their lack of efficacy as maintenance therapy 
combined with their significant side effects has prompted 
the need for additional long-term therapies. In the study 
mentioned above, 89% of the corticosteroid-treated children 
had either inactive or mild disease by 3 months after the 
start of therapy.13 However, at 1 year, 45% of children who 
had required early use of corticosteroids were considered 
corticosteroid-dependent because they needed either continu-
ous or repeated courses of the medication. Ultimately, 5% of 
all corticosteroid-treated patients required colectomy within 
1 year of treatment initiation, and the indication for colec-
tomy in each case was corticosteroid-resistant disease. These 
results were seen despite the concomitant use of 5-ASAs in 
86% of the children, thiopurine immunomodulators in 61%, 
and infliximab (Remicade; Janssen Biotech, Horsham, PA), 
an anti-TNF-α agent, in 12%. Similar results were found in a 
retrospective, population-based, inception cohort study per-
formed from 1940 to 2001.14 Approximately 40% of patients 
with UC received their first treatment course of corticoster-
oids before the age of 19 years. By 30 days after corticoster-
oid initiation, complete disease remission was seen in 50% of 
children, partial remission in 29%, and no response in 21%. 
The 1-year outcomes revealed a prolonged response in 57% 
of children, corticosteroid dependence in 14%, and surgical 
resection in 29%. The difference in surgery rates between the 
two studies may be related to differences in the cohort sizes, 
ages of the subjects, and/or practice patterns.
There is significant concern regarding corticosteroid tox-
icity in children because of well-recognized side effects such 
as hyperglycemia, hypertension, growth failure, weight gain, 
adrenal suppression, and mood disturbances. A retrospective 
review comparing preoperative major steroid-related com-
plications in children and adults with UC found significantly 
higher incidences of growth failure, osteoporosis, glaucoma, 
and cataracts in children, with no significant differences in the 
preoperative total dosage of corticosteroids per body weight 
or body surface area.5 Therefore, corticosteroid-sparing treat-
ment approaches are being used more readily; for example, 
clinicians may consider concomitant therapy with thiopurine 
immunomodulators or anti-TNF-α medications earlier in the 
treatment course of children with anticipated corticosteroid-
dependent UC.15
Thiopurine immunomodulators
Frequently used in pediatric UC for the maintenance of 
disease remission, the purine analogue 6-mercaptopurine 
(6-MP) and its prodrug, azathioprine (AZA), work by 
inhibiting RNA and DNA synthesis, thereby downregulating 
cytotoxic T-cell activity.7 A prospective, multicenter, inception 
cohort study found that 197 of 394 children with UC had 
received a thiopurine immunomodulator, and these patients 
had more moderate-to-severe disease at diagnosis than those 
who were never treated with this class of medications.16 Of 
the 133 patients evaluable at 1 year, 49% had corticosteroid-
free inactive disease without the need for rescue therapy 
such as infliximab or surgery, while an additional 10% had 
corticosteroid-free mild disease. A Kaplan–Meier analysis 
found that 73% of thiopurine immunomodulator–treated 
children were likely to remain free of rescue therapy at 
1 year. While thiopurine immunomodulators have clear 
corticosteroid-sparing benefits, they are less useful for the 
induction of disease remission, since studies suggest that 
treatment for up to 3–4 months is necessary before a 
therapeutic response can be seen.17
Knowledge of the metabolism of thiopurine immuno-
modulators is paramount to enhancing their efficacy and 
minimizing side effects. AZA is a prodrug that, once absorbed, 
is rapidly converted to 6-MP.18 The first intermediate 
metabolite of 6-MP, thioinosine monophosphate, is then 
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converted to the thioguanine nucleotides (6-TGN), which 
mediate the cytotoxic and immunosuppressive effects of 
6-MP. However, by an alternate pathway, 6-MP can be 
methylated by the thiopurine methyltransferase (TPMT) 
enzyme to 6-methylmercaptopurine (6-MMP). Little is 
known about the mechanistic role of 6-MMP, but genetic 
variability in the TPMT enzyme is responsible for the indi-
vidual differences seen in the effectiveness and toxicity of 
thiopurine immunomodulators.
Adverse reactions associated with the use of these 
medications include allergic or idiosyncratic events, 
myelosuppression, hepatotoxicity, and malignancy.18 
Allergic or idiosyncratic reactions, which include a flu-
like illness, malaise, fever, rash, abdominal pain, and 
pancreatitis, are seen in 5%–10% of patients and are 
independent of the thiopurine immunomodulator dose. Bone 
marrow suppression, especially leukopenia, is mediated 
by high levels of 6-TGN and is the most common dose-
dependent toxicity of thiopurine immunomodulators seen 
in 2.2%–15% of patients. Elevated levels of the metabolite 
6-MMP, however, have been associated with hepatotoxicity, 
defined as transaminase levels greater than twice normal. In 
terms of malignancy potential, it has been recognized that 
immunosuppression in general can be associated with an 
increased risk of lymphoma. Specifically, a meta-analysis 
reviewed six studies of IBD patients treated with AZA or 
6-MP and found a pooled relative risk of lymphoma of 4.18 
(95% confidence interval: 2.07–7.51).19
Assaying TPMT enzymatic activity prior to initiating a 
thiopurine immunomodulator can aid clinicians in selection 
of the optimal starting dose.18 Patients with normal-to-high 
enzyme activity (89% of individuals) can generally receive 
2–2.5 mg/kg/day of AZA or 1–1.5 mg/kg/day of 6-MP. 
Children with intermediate activity (11% of individuals) 
can usually start at 30%–50% of the standard dose, with 
escalation as tolerated based on blood counts and 6-TGN 
concentrations. However, an alternate therapeutic agent 
should be considered for patients with low or absent enzyme 
activity (0.3% of individuals) because of the toxicity associ-
ated with elevated 6-TGN levels. As suggested above, 6-MP 
metabolite levels can be monitored throughout treatment, 
and a 6-TGN level $ 235 pmol/8 × 108 red blood cells has 
been associated with a favorable therapeutic response.20 
A retrospective review of 101 children with IBD receiving 
a thiopurine immunomodulator found that dose adjustment 
using 6-MP metabolite levels was associated with a statisti-
cally significant increased likelihood of being in remission, 
fewer disease exacerbations requiring hospitalization, 
decreased corticosteroid use, and administration of higher 
thiopurine immunomodulator doses.20
Calcineurin inhibitors
Calcineurin inhibitors, including cyclosporine and tacroli-
mus, have historically been used in the management of 
acute severe or fulminant colitis, especially in the setting of 
corticosteroid-refractory or -dependent disease. These agents 
work by blocking transcription of proinflammatory cytokines 
and inhibiting T-cell activation. They are typically used for 
only 3–4 months as a bridge to thiopurine immunomodula-
tors or future colectomy because they have a limited role 
in the maintenance of remission. Additionally, widespread 
use of calcineurin inhibitors has been limited by potentially 
serious side effects, including nephrotoxicity, infections, 
seizures, hypomagnesemia, hypertension, hypertrichosis, 
and headaches, which may be improved by oral instead of 
intravenous medication administration.21
A retrospective, single-center review identified 14 children 
with fulminant colitis, marked by fever, severe abdominal 
pain, and six or more grossly bloody stools per day, that 
was unresponsive to intravenous methylprednisolone, total 
parenteral nutrition, and complete bowel rest.22 Each patient 
was initiated on oral cyclosporine 4–8 mg/kg/day, with 
adjustment of the dose to achieve whole blood trough levels 
of 150–300 ng/mL. Three patients underwent colectomy 
within 3 weeks of starting cyclosporine, but eleven patients 
(78%) had a complete response within 2–9 days, with sub-
sequent discharge from the hospital on cyclosporine and 
prednisone. Seven of the eleven discharged patients had a 
flare of their symptoms and required colectomy within 1 year 
of treatment with cyclosporine; only four patients (28%) 
were able to avoid colectomy during the 6-month to 5-year 
follow-up period. No serious adverse events were reported, 
but five patients developed mild hypertension, four had an 
increase in serum creatinine, and six became mildly hirsute. 
More favorable outcomes were seen in a recent retrospective 
review from Italy describing 32 children with severe UC that 
was either dependent on or unresponsive to corticosteroids.23 
They were treated with oral cyclosporine (5 mg/kg/day 
adjusted to achieve whole blood levels of 150–250 ng/mL) 
while being maintained on a 5-ASA and AZA. Twenty-eight 
patients (87%) responded within 7–15 days with a reduction 
in the number of stools, disappearance of visible blood, and 
cessation of abdominal pain. Four patients did not have an 
immediate response, so underwent colectomy, while five of 
the 28 initial responders required a colectomy after a mean 
period of 19.8 months. Twenty-three patients (72%) avoided 
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surgery during the mean follow-up period of 5.1 years, 
with no major cyclosporine-related side effects except for 
headaches in five patients. Together, these reviews suggest a 
benefit of cyclosporine in achieving rapid clinical remission 
and avoiding emergent colectomy in children with severe 
or fulminant colitis. Most initial responders will ultimately 
require surgery, but the procedure can occur in a more 
elective fashion with optimization of nutritional status and 
other perioperative factors.
Tacrolimus is another calcineurin inhibitor that is less 
frequently prescribed but can also be used in the setting 
of severe refractory UC. A retrospective study reviewed 
46 children and young adults who were started on oral 
tacrolimus due to severe colitis unresponsive to intravenous 
corticosteroids.24 Tacrolimus was initiated at 0.1 mg/kg/dose 
twice daily and titrated to yield trough levels of 10–15 ng/mL 
for induction and 5–10 ng/mL for maintenance. Prior to the 
initiation of tacrolimus, 67% of patients had severe disease 
and 33% had moderate disease. The median length of hospital 
stay after starting tacrolimus was 10 days, at which point 
only 4% of patients had severe disease, 30% had moderate 
disease, 50% had mild disease, and 15% were in remission. 
Overall, colectomies were performed in 46% of the patients; 
three of these procedures were performed during the initial 
hospitalization, six within the first 3 months of follow-up, 
and twelve during the remainder of the follow-up period 
(median 11.8 months). Common side effects included 
hypertension, tremor, hyperglycemia, headache, infection, 
and nephrotoxicity. Like cyclosporine, tacrolimus may be a 
useful induction agent for severe, corticosteroid-refractory 
UC, but the long-term colectomy rate remains substantial, 
so alternative agents need to be considered.
Antibiotics and probiotics
It is theorized that IBD is caused, in part, by a dysregulated 
immune response to commensal intestinal flora. For this 
reason, antibiotics are often employed in disease manage-
ment as a means of favorably altering the gut microbiome. 
There are limited data supporting antibiotic use in pediatric 
UC. However, in 2011, a systemic review was published of 
randomized controlled trials evaluating antibiotics in adults 
with IBD.25 For active UC, nine studies with 662 patients 
were reviewed, with each study using different antibiotics 
either alone or in combination. Overall, the authors found a 
statistically significant benefit for antibiotics inducing dis-
ease remission. Antibiotics are also frequently prescribed for 
the treatment of pouchitis, which is a complication seen in 
20%–50% of patients following proctocolectomy with ileal 
pouch-anal anastomosis.26 Pouchitis often presents acutely 
with abdominal pain, diarrhea, and hematochezia, and is 
diagnosed based on clinical, endoscopic, and histologic 
features. It likely arises from an overgrowth of bacteria within 
the pouch, so first-line treatment includes a short course of 
an antibiotic such as metronidazole or ciprofloxacin.
Probiotics may be an alternate therapy for the management 
of recurrent or chronic pouchitis,26 but studies are also 
showing a role for probiotics in the induction and maintenance 
of remission of active UC. Probiotics are nonpathogenic 
bacteria normally found within the intestinal microflora 
that can decrease secretion of proinflammatory cytokines, 
increase production of anti-inflammatory cytokines, and 
enhance the integrity of the mucosal barrier.7 Several adult 
studies have recently investigated the use of various probiotic 
preparations, including VSL#3,27,28 Escherichia coli Nissle 
1917,29 and Bifidobacterium longum,30 for the induction and 
maintenance of disease remission with promising results. 
A prospective, double-blind, placebo-controlled, 1-year study 
assessed the efficacy of the probiotic preparation VSL#3 in 
achieving disease remission in children newly diagnosed with 
UC.31 Children were randomized to receive either VSL#3 or 
placebo in addition to corticosteroid induction and 5-ASA 
maintenance therapy. In the VSL#3 group, 92.8% of children 
had remission of their disease, compared to only 36.4% in the 
placebo group, with no reported side effects. Additionally, 
endoscopic and histologic scores were significantly better 
in the children receiving VSL#3. While these results are 
encouraging, more prospective studies are needed of this and 
other probiotic preparations in larger numbers of children 
to support the benefit of probiotics in the management of 
pediatric UC.
Anti-TNF-α agents
Infliximab
Treatment options for both the induction and maintenance of 
remission of moderate-to-severe UC have greatly improved 
with the introduction of the biologic agents, especially the 
anti-TNF-α medications. Infliximab is a genetically engi-
neered chimeric immunoglobulin G1 monoclonal antibody 
consisting of 75% human and 25% murine sequences.32 
It binds to both circulating and cell-bound forms of the 
proinflammatory cytokine TNF-α, thereby neutralizing 
TNF-α and causing apoptosis of activated lymphocytes. 
Infliximab was first established as a treatment for CD, but 
recognition that TNF-α is also found in the blood, colonic tis-
sue, and stools of patients with UC led to further investigation 
of the use of infliximab for this disease. It has been shown to 
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be effective in inducing clinical remission and reducing the 
need for colectomy in adults with UC resistant to 5-ASAs, 
corticosteroids, and thiopurine immunomodulators.33 In 2005, 
the results were published from two randomized, double-
blind, placebo-controlled studies (the Active Ulcerative 
Colitis Trials [ACT] 1 and 2) that evaluated the efficacy of 
infliximab for the induction and maintenance of remission 
of UC in adults.34 In each study, 364 patients who had 
moderate-to-severe UC despite treatment with corticosteroids 
or thiopurine immunomodulators were randomized to receive 
either infliximab (5 or 10 mg/kg intravenously) or placebo at 
weeks 0, 2, and 6, then every 8 weeks for a total of 46 weeks 
in ACT 1 or 22 weeks in ACT 2. At week 8 in ACT 1, 69% 
of patients receiving 5 mg/kg of infliximab and 61% of those 
receiving 10 mg/kg had a clinical response, compared to 37% 
of patients in the placebo group. Similar results were found in 
ACT 2, where 64% of patients in the 5 mg/kg of infliximab 
group and 69% in the 10 mg/kg group had a clinical response 
at week 8, compared to 29% of patients receiving placebo. 
Overall, significantly more patients in the infliximab group 
sustained this clinical response, demonstrated mucosal 
healing, and had greater decreases in their mean daily 
corticosteroid dose.
A number of single-center reports, as shown in Table 2, 
have reviewed the use of infliximab in the pediatric UC 
population under the following disease circumstances 
with encouraging results: fulminant colitis unresponsive 
to corticosteroids; an acute exacerbation of colitis; and 
corticosteroid-dependent or -refractory disease.35–43 In 2010, 
a larger, prospective, multicenter, inception cohort study of 
a subgroup of children with UC enrolled in the Pediatric 
Inflammatory Bowel Disease Collaborative Research Group 
Registry identified 52 children who required treatment 
with infliximab.44 At diagnosis, 80% of these children had 
moderate or severe disease, compared to 66% of the children 
not receiving infliximab. Additionally, these children were 
more likely to have received corticosteroids or thiopurine 
immunomodulators by 3 months following diagnosis. 
Infliximab was initiated at a median time of 9 months from 
diagnosis because of corticosteroid-refractory disease in 
63% of patients and corticosteroid-dependent disease in 
35%. Continuous maintenance infliximab was used in 65% 
of patients, episodic therapy in 21%, and episodic converted 
to continuous maintenance therapy in 6%. Follow-up at 
3, 6, 12, and 24 months found corticosteroid-free inactive 
disease as measured by physician global assessment in 
12/47 (26%), 12/44 (27%), 15/39 (38%), and 6/28 (21%) 
patients, respectively. When only patients on continuous 
maintenance therapy were considered, approximately 50% 
had corticosteroid-free inactive or mild disease at each 
Table 2 Case series reporting the use of infliximab in the treatment of pediatric ulcerative colitis
Authors Study population Outcomes measured Conclusions
Mamula et al35 9 children Clinical response (LCAi, PGA)  
at 2 days and 2 weeks
Median LCAi score decreased from 11 before  
infusion to 1 at 2 days and 2 weeks after infusion;  
decreased disease activity in 7 patients by PGA
Mamula et al36 17 children Avoidance of colectomy  
or escalation of medical therapy
14 patients with short-term response;  
10 of 16 patients with sustained response (.9 months)
Russell and Katz37 14 children Clinical response (LCAi)  
by week 6
9 patients with sustained decrease of LCAi to #2
Eidelwein et al38 12 children Clinical response (PGA) 9 patients with complete short-term response at 2 weeks, 
3 with partial response; 8 patients with long-term  
response at 6 months
Fanjiang et al39 27 children Clinical response (LCAi);  
avoidance of colectomy and CSs
Successful treatment in 75% of acutely ill and 27%  
of chronically ill patients; mean follow-up 27 months
Cucchiara et al40 22 children Clinical response (LCAi)  
by week 54
12 responders, 6 partial responders, 4 nonresponders;  
7 patients required colectomy
McGinnis and  
Murray41
40 children Clinical response  
(Truelove and Witts criteria)
28 responders, median follow-up 19 months
Hyams et al44 52 children Clinical response (PGA) CS-free inactive disease in 26%, 27%, 38%, and 21%  
of patients at 3, 6, 12, and 24 months
Tiemi et al42 21 children 
(7 UC, 14 CD)
Clinical response  
(clinical manifestations, disease  
activity indices, CS use)  
by week 22
18 patients in remission, 3 patients with clinical  
improvement; significant improvement in disease activity  
indices; 6 of 15 patients discontinued CSs
Hyams et al43 60 children Clinical response (disease activity  
indices) by week 8
44 responders
Abbreviations: LCAI, Lichtiger colitis activity index; PGA, physician global assessment; CS, corticosteroid; UC, ulcerative colitis; CD, Crohn’s disease.
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assessment point. Kaplan–Meier analysis determined the 
likelihood of remaining colectomy-free to be 79%, 75%, 
72%, and 61% at each respective time point. Notably, no 
adverse events were reported. This study highlights the role 
of infliximab as both induction and maintenance therapy 
for children with moderate-to-severe UC unresponsive to 
or dependent on corticosteroids.
While generally safe and well tolerated, infliximab has 
been associated with such side effects as infusion reac-
tions, infections, and malignancy. Infusion reactions are 
the most frequent complication occurring in either an acute 
or a delayed fashion. Acute reactions are marked by blood 
pressure instability, chest pain, dyspnea, and laryngospasm, 
while delayed hypersensitivity symptoms include fever, 
malaise, and arthralgias. A multicenter study of children with 
IBD reviewed a total of 1652 infliximab infusions given to 
243 subjects over a period of 3 years.45 Overall, 40 patients 
experienced 60 infusion reactions, representing 16.5% of 
patients and 3.6% of infusions. Premedication with antipyret-
ics, antihistamines, and/or corticosteroids did not necessar-
ily prevent these reactions but did seem useful in avoiding 
subsequent ones. The development of antibodies to inflix-
imab (human antichimeric antibodies [HACA]) has been 
associated with an increased risk of infusion reactions and a 
diminished response to infliximab itself. A 2004 retrospective 
review identified HACA in twelve of 34 children with IBD 
who had conclusive antibody testing.46 Infusion reactions 
occurred during 13.8% of the infusions given to children 
with positive HACA and only 3.6% of the infusions in those 
children with negative HACA. Recent studies have shown 
that continuous maintenance therapy with infliximab results 
in better outcomes because episodic therapy leads to a higher 
frequency of HACA development; maintenance infusions are 
typically given every 8 weeks, but shorter or longer intervals 
can be recommended on an individual basis.6 Additionally, 
in the study mentioned above, concomitant immunomodula-
tory therapy was significantly associated with a lower risk 
of developing HACA and protected against having a high 
titer of antibodies.46
Administration of infliximab is also associated with an 
increased susceptibility to infections, including pneumonia, 
abscesses, and sepsis, which have been reported in 3.9% of 
children with CD.32 Its use is contraindicated in the setting 
of active tuberculosis or any other serious infection, and 
screening for tuberculosis prior to the initiation of therapy 
is recommended. As previously mentioned, immunosup-
pressed patients have an increased long-term risk of the 
development of lymphoma, but recent reports have described 
the association of concomitant therapy with infliximab and 
a thiopurine immunomodulator with the development of 
hepatosplenic T-cell lymphoma (HSTCL) in young patients 
with IBD.47 The risk of developing HSTCL in this population 
is low (∼0.05%), but this form of lymphoma has an aggres-
sive course that is most often fatal. Clinicians are encouraged 
to have a high index of suspicion for HSTCL in patients 
on concurrent immunomodulatory therapy and to monitor 
routinely for such symptoms as fever, fatigue, elevation of 
liver enzymes, anemia, and leukopenia.
It is essential to monitor for infliximab nonresponse and 
loss of response in patients treated with the medication. 
Primary nonresponse is defined as the “lack of improvement 
of clinical signs and symptoms with induction therapy,” 
suggesting that the symptoms may not due to an inflamma-
tory disease, as with irritable bowel syndrome, or that TNF-α 
is not central to the inflammatory process.48 While primary 
nonresponse is not common in children, a proportion of 
patients who initially have an appropriate induction response 
to infliximab may eventually lose this response, known as 
secondary nonresponse. This loss of response can be due to 
increased drug clearance, HACA formation, a change in the 
pathophysiology of the inflammation, or increased symptoms 
not related to inflammation. If a child has a decreased dura-
tion or magnitude of response to infliximab, then the clini-
cian can consider evaluating for HACA, increasing the dose, 
shortening the interval of administration, and/or adding a 
concomitant immunomodulator. However, if the child has a 
complete loss of response, then thought should be given to 
reevaluating the disease, switching to another anti-TNF-α 
agent as discussed below, or investigating possible surgical 
options.
Adalimumab and certolizumab
Adalimumab (Humira; Abbott Laboratories, Chicago, 
IL) is a fully humanized immunoglobulin G1 monoclonal 
antibody to TNF-α that is generally used in children who 
either fail to tolerate or become intolerant to infliximab. It 
has recently been shown to be more effective than placebo 
for the induction and maintenance of remission in adults 
with moderate-to-severe UC, despite concomitant treatment 
with oral corticosteroids or thiopurine immunomodulators.49 
This multicenter, double-blind, placebo-controlled trial ran-
domly assigned 494 patients to receive either adalimumab 
(160 mg subcutaneously at week 0, 80 mg at week 2, then 
40 mg every other week) or placebo. At week 8, significantly 
more patients receiving adalimumab were in clinical remis-
sion (16.5%) compared to those receiving placebo (9.3%); 
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at week 52, the results were similar, with 17.3% and 8.5% 
of patients in remission, respectively. Data is lacking on the 
use of adalimumab in pediatric UC. A small, single-center 
retrospective review from 2008 described ten children with 
IBD (7 CD, 3 UC) who had been treated with adalimumab 
following infliximab intolerance or failure; eight patients 
responded to adalimumab, while two patients required surgi-
cal management.50
Certolizumab (Cimzia; UCB, Brussels, Belgium) is a 
pegylated monoclonal antibody to TNF-α that is adminis-
tered subcutaneously and has a longer half-life than the other 
anti-TNF-α agents because of its pegylated portion.51 Adult 
studies suggest the efficacy of certolizumab is comparable 
to the other anti-TNF-α therapies. However, the paucity of 
data on its use in children with IBD has led to its current 
consideration as only a rescue therapy in those patients who 
have failed treatment with other agents.
Summary of the treatment  
approach to pediatric UC
The treatment of pediatric UC is sequential and tailored to the 
severity of disease activity.52 Patients with mild-to-moderate 
disease are frequently initiated on a 5-ASA preparation. If 
they do not respond or if the disease is more moderate to 
severe at presentation, then a course of corticosteroids can 
be trialed, with transition to a thiopurine immunomodulator 
for maintenance therapy. Alternately, infliximab has been 
increasingly used as a corticosteroid-sparing agent for both 
the induction and maintenance of remission of moderate-
to-severe disease. Severe or fulminant colitis requires the 
prompt initiation of appropriate medical and/or surgical 
therapies in order to minimize morbidity.21 Intravenous cor-
ticosteroids have been the mainstay of treatment for severe 
UC since the first studies supporting their use were published 
in 1955.53 However, corticosteroid refractoriness is common 
in this patient population, so second-line therapies, including 
calcineurin inhibitors, anti-TNF-α agents, and surgery, need 
to be considered early in the treatment course.
Generation and validation of the Pediatric Ulcerative 
Colitis Activity Index (PUCAI) has led to a more robust defi-
nition of acute severe colitis and has allowed clinicians to bet-
ter predict the outcomes of children admitted for intravenous 
corticosteroids, thus facilitating a more timely introduction 
of second-line therapies.54,55 The PUCAI score ranges from 
0 to 85, with points given to the degree of abdominal pain, 
amount of rectal bleeding, stool consistency, number of stools 
per day, presence of nocturnal stools, and activity level; a 
PUCAI score $ 65 is consistent with severe disease activity. 
In a prospective, multicenter study of 128 children with severe 
UC, 37 children failed intravenous corticosteroids within a 
mean of 10.5 days and subsequently received cyclosporine 
(3%), colectomy (8%), or infliximab (89%).56 Long-term 
follow-up revealed that 25 of the 33 patients treated with 
infliximab were responders. The authors also determined that 
the PUCAI score on days 3 and 5 of hospitalization could 
be used to decide the timing of introduction of second-line 
therapy in these patients with severe colitis. A child with a 
PUCAI score . 45 on day 3 should be prepared for second-
line therapy, while a score . 65 on day 5 should prompt 
initiation of that therapy.21
With the advent of anti-TNF-α agents, the use of 
calcineurin inhibitors as second-line agents has significantly 
decreased in the pediatric UC population because of their lack 
of efficacy as maintenance therapy and the toxicities associ-
ated with their use. Anti-TNF-α agents, especially infliximab, 
are effective in the acute management of severe or fulminant 
colitis that is unresponsive to corticosteroids; their additional 
utility as maintenance therapy and improved side-effect profile 
have made them a more favorable second-line therapy than 
calcineurin inhibitors. While medical therapy in the setting of 
severe or fulminant colitis is generally preferred in children, 
colectomy should also be seriously considered, especially in 
the presence of life-threatening hemorrhage, perforation, or 
peritonitis. Other standard indications for surgical intervention 
include the following: worsening symptoms despite maximal 
medical management; history of chronic corticosteroid use 
with significant side effects; history of long-standing, exten-
sive disease for greater than 10 years; or delay in growth 
and maturation. The surgical procedure of choice in UC is a 
proctocolectomy with an ileal pouch-anal anastomosis, which 
preserves anorectal continence and has been associated with 
excellent long-term results.1,26
Conclusions
The treatment of pediatric UC is an expanding field due to 
the increased understanding of the genetic and immunologi-
cal basis of the disease. Clinicians are limiting the use of 
corticosteroids, given their lack of efficacy as maintenance 
medications and significant side-effect profile, in favor of 
newer therapies with enhanced efficacy. Anti-TNF-α agents, 
including infliximab, offer important therapeutic alternatives 
because they target a specific cytokine that is essential in the 
pathogenesis of the disease. While promising data are arising 
from adult studies, more research is needed on the use of these 
new medications in children, including comparative studies 
of the multiple anti-TNF-α agents. Ultimately, the goals of 
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the treatment of pediatric UC remain the same, and clinicians 
continue to aim for improved control of the disease, adequate 
growth, and enhanced quality of life in their patients.
Disclosure
Maria Oliva-Hemker received a research grant from Abbott 
Immunology. Gia M Bradley reports no conflicts of interest 
in this work.
References
  1.  Hyams JS. Inflammatory bowel disease. Pediatr Rev. 2005;26(9): 
314–320.
  2.  Cuffari C. Inflammatory bowel disease in children: a pediatrician’s 
perspective. Minerva Pediatr. 2006;58(2):139–157.
  3.  Sawczenko A, Sandhu BK. Presenting features of inflamma-
tory bowel disease in Great Britain and Ireland. Arch Dis Child. 
2003;88(11):995–1000.
  4.  Hyams J, Davis P, Lerer T, et al. Clinical outcome of ulcerative proctitis 
in children. J Pediatr Gastroenterol Nutr. 1997;25(2):149–152.
  5.  Uchida K, Araki T, Toiyama Y, et al. Preoperative steroid-related 
complications in Japanese pediatric patients with ulcerative colitis. Dis 
Colon Rectum. 2006;49(1):74–79.
  6.  Carvalho R, Hyams JS. Diagnosis and management of inflammatory 
bowel disease in children. Semin Pediatr Surg. 2007;16(3):164–171.
  7.  Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcer-
ative colitis. Expert Opin Pharmacother. 2006;7(14):1907–1918.
  8.  Devlin SM, Panaccione R. Evolving inflammatory bowel disease treat-
ment paradigms: top-down versus step-up. Gastroenterol Clin North 
Am. 2009;38(4):577–594.
  9.  Quiros JA, Heyman MB, Pohl JF, et al. Safety, efficacy, and pharma-
cokinetics of balsalazide in pediatric patients with mild-to-moderate 
active ulcerative colitis: results of a randomized, double-blind study.   
J Pediatr Gastroenterol Nutr. 2009;49(5):571–579.
  10.  Tolia V, Massoud N, Klotz U. Oral 5-aminosalicyclic acid in 
children with colonic chronic inflammatory bowel disease: clinical 
and pharmacokinetic experience. J Pediatr Gastroenterol Nutr. 
1989;8(3):333–338.
  11.  D’Agata ID, Vanounou T, Seidman E. Mesalamine in pediatric 
inflammatory bowel disease: a 10–year experience. Inflamm Bowel 
Dis. 1996;2(4):229–235.
  12.  Heyman MB, Kierkus J, Spenard J, Shbaklo H, Giguere M. 
Efficacy and safety of mesalamine suppositories for treatment of 
ulcerative proctitis in children and adolescents. Inflamm Bowel Dis. 
2010;16(11):1931–1939.
  13.  Hyams J, Markowitz J, Lerer T, et al. The natural history of corticos-
teroid therapy for ulcerative colitis in children. Clin Gastroenterol 
Hepatol. 2006;4(9):1118–1123.
  14.  Tung J, Loftus EV Jr, Freese DK, et al. A population-based study of 
the frequency of corticosteroid resistance and dependence in pediatric 
patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 
2006;12(12):1093–1100.
  15.  Oliva-Hemker  M,  Escher  JC,  Moore  D,  et  al.  Refractory 
inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr. 
2008;47(2):266–272.
  16.  Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use 
in children with ulcerative colitis: a prospective multicenter registry 
study. Am J Gastroenterol. 2011;106(5):981–987.
  17.  Kirschner BS. Safety of azathioprine and 6-mercaptopurine in 
pediatric patients with inflammatory bowel disease. Gastroenterology. 
1998;115(4):813–821.
  18.  Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel 
disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 
2004;2(9):731–743.
  19.  Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. 
Increased risk of lymphoma among inflammatory bowel disease 
patients treated with azathioprine and 6-mercaptopurine. Gut. 
2005;54(8):1121–1125.
  20.  Banerjee S, Bishop WP. Evolution of thiopurine use in pediatric inflam-
matory bowel disease in an academic center. J Pediatr Gastroenterol 
Nutr. 2006;43(3):324–330.
  21.  Turner D, Travis SP, Griffiths AM, et al. Consensus for managing 
acute severe ulcerative colitis in children: a systematic review and joint 
statement from ECCO, ESPGHAN, and the Porto IBD Working Group 
of ESPGHAN. Am J Gastroenterol. 2011;106(4):574–588.
  22.  Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine 
for the treatment of fulminant ulcerative colitis in children. Immediate 
response, long-term results, and impact on surgery. Dis Colon Rectum. 
1995;38(5):474–479.
  23.  Castro M, Papadatou B, Ceriati E, et al. Role of cyclosporin in prevent-
ing or delaying colectomy in children with severe ulcerative colitis. 
Langenbecks Arch Surg. 2007;392(2):161–164.
  24.  Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse 
events in children and young adults undergoing tacrolimus therapy for 
steroid-refractory colitis. Inflamm Bowel Dis. 2011;17(1):22–29.
  25.  Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflam-
matory bowel disease: a systematic review and meta-analysis. Am J 
Gastroenterol. 2011;106(4):661–673.
  26.  Alexander F. Complications of ileal pouch anal anastomosis. Semin 
Pediatr Surg. 2007;16(3):200–204.
  27.  Sood A, Midha V , Makharia GK, et al. The probiotic prepara-
tion, VSL#3 induces remission in patients with mild-to-moderately 
active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(11): 
1202–1209.
  28.  Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-
moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a 
standard pharmaceutical treatment: a double-blind, randomized, placebo-
controlled study. Am J Gastroenterol. 2010;105(10):2218–2227.
  29.  Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical 
trial: probiotic treatment of acute distal ulcerative colitis with rectally 
administered Escherichia coli Nissle 1917 (EcN). BMC Complement 
Altern Med. 2010;10:13.
  30.  Fujimori S, Gudis K, Mitsui K, et al. A randomized controlled trial 
on the efficacy of synbiotic versus probiotic or prebiotic treatment to 
improve the quality of life in patients with ulcerative colitis. Nutrition. 
2009;25(5):520–525.
  31.  Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, 
Staiano A. Effect of a probiotic preparation (VSL#3) on induction 
and maintenance of remission in children with ulcerative colitis. Am J 
Gastroenterol. 2009;104(2):437–443.
  32.  Veres G, Baldassano RN, Mamula P. Infliximab therapy in 
children and adolescents with inflammatory bowel disease. Drugs. 
2007;67(12):1703–1723.
  33.  Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor 
alpha blocking agents for induction of remission in ulcerative colitis. 
Cochrane Database Syst Rev. 2006;3:CD005112.
  34.  Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction 
and maintenance therapy for ulcerative colitis. N Engl J Med. 
2005;353(23):2462–2476.
  35.  Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA,   
Baldassano RN. Infliximab as a novel therapy for pediatric ulcerative 
colitis. J Pediatr Gastroenterol Nutr. 2002;34(3):307–311.
  36.  Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. 
Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr 
Gastroenterol Nutr. 2004;38(3):298–301.
  37.  Russell GH, Katz AJ. Infliximab is effective in acute but not 
chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr. 
2004;39(2):166–170.
  38.  Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab 
efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005;11(3): 
213–218.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
133
Treatment of pediatric ulcerative colitisBiologics: Targets & Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/biologics-targets--therapy-journal
Biologics: Targets & Therapy is an international, peer-reviewed journal 
focusing on the patho-physiological rationale for and clinical applica-
tion of Biologic agents in the management of autoimmune diseases, 
cancers or other pathologies where a molecular target can be identified. 
This journal is indexed on PubMed Central, CAS, EMBase, Scopus 
and the Elsevier Bibliographic databases. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Biologics: Targets and Therapy 2012:6
  39.  Fanjiang G, Russell GH, Katz AJ. Short- and long-term response to 
and weaning from infliximab therapy in pediatric ulcerative colitis.   
J Pediatr Gastroenterol Nutr. 2007;44(3):312–317.
  40.  Cucchiara S, Romeo E, Viola F, et al. Infliximab for pediatric ulcerative 
colitis: a retrospective Italian multicenter study. Dig Liver Dis. 2008; 
40 Suppl 2:S260–S264.
  41.  McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children 
and adolescents. J Clin Gastroenterol. 2008;42(8):875–879.
  42.  Tiemi J, Komati S, Sdepanian VL. Effectiveness of infliximab in 
Brazilian children and adolescents with Crohn disease and ulcerative 
colitis according to clinical manifestations, activity indices of inflam-
matory bowel disease, and corticosteroid use. J Pediatr Gastroenterol 
Nutr. 2010;50(6):628–633.
  43.  Hyams J, Damaraju L, Blank M, et al. Induction and maintenance 
therapy with infliximab for children with moderate to severe ulcerative 
colitis. Clin Gastroenterol Hepatol. 2012;10(4):391–399.
  44.  Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab 
therapy in children with ulcerative colitis. Am J Gastroenterol. 
2010;105(6):1430–1436.
  45.  Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and 
infusion reactions with infliximab: results from a pediatric inflammatory 
bowel disease consortium. Inflamm Bowel Dis. 2005;11(5):442–446.
  46.  Miele E, Markowitz JE, Mamula P, Baldassano RN. Human 
antichimeric antibody in children and young adults with inflammatory 
bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 
2004;38(5):502–508.
  47.  Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic 
T-cell lymphoma in adolescents and young adults with Crohn’s disease: 
a cautionary tale? Inflamm Bowel Dis. 2007;13(8):1024–1030.
  48.  Yanai H, Hanauer SB. Assessing response and loss of response to biological 
therapies in IBD. Am J Gastroenterol. 2011;106(4):685–698.
  49.  Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces 
and maintains clinical remission in patients with moderate-to-severe 
ulcerative colitis. Gastroenterology. 2012;142(2):257–265.
  50.  Noe JD, Pfefferkorn M. Short-term response to adalimumab 
in childhood inflammatory bowel disease. Inflamm Bowel Dis. 
2008;14(12):1683–1687.
  51.  Bousvaros A. Use of immunomodulators and biologic therapies in 
children with inflammatory bowel disease. Expert Rev Clin Immunol. 
2010;6(4):659–666.
  52.  Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel 
disease therapy: current state-of-the-art. Curr Opin Gastroenterol. 
2011;27(4):346–357.
  53.  Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on 
a therapeutic trial. Br Med J. 1955;2(4947):1041–1048.
  54.  Turner D, Otley AR, Mack D, et al. Development, validation, and 
evaluation of a pediatric ulcerative colitis activity index: a prospective 
multicenter study. Gastroenterology. 2007;133(2):423–432.
  55.  Turner D, Hyams J, Markowitz J, et al. Appraisal of the pediatric 
ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 
2009;15(8):1218–1223.
  56.  Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: 
a prospective multicenter study of outcomes and predictors of response. 
Gastroenterology. 2010;138(7):2282–2291.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
134
Bradley and Oliva-Hemker